A sensitive and specific UPLC-MS/MS analysis and preliminary pharmacokinetic characterization of S-oxiracetam in Beagle dogs

Abstract

Abstract: AIM: To develop a sensitive and specific ultra performance liquid chromatography-electrospray ionization-tandem mass spectrometry (UPLC-ESI-MS/MS) method for the identification and quantification of S-oxiracetamin in Beagle dog plasma.METHODS: The method involved the addition of piracetam as internal standards, protein-precipitation, UPLC separation, and quantification by MS/MS system using positive electrospray ionization in the multiple reaction monitoring mode (MRM). An HP Amide C₁₈ column (100 mm×3.00 mm, 5 μm) was used as the analytical column, while a mixture of methanol-water was used as the mobile phase. The precursor/product ion transitions selected were m/z 159.0/114.1 for S-oxiracetam and m/z 143.0/126.1 for I.S.RESULTS: The lower limit of quantification of S-oxiracetam was 0.05 μg/mL.The method was linear in the concentration range of 0.05-50 μg/mL.The intra-day and inter-day precisions (RSD) were within 15.0% for the analytes. S-oxiracetam was proved to be stable during all sample storage, preparation and analytical periods.The method was successfully applied to a pharmacokinetic study in dogs after intragastric administration of S-oxiracetam with a dose of 50 mg/kg.CONCLUSION: The proposed method enables unambiguous identification and quantification for the preliminary pharmacokinetic studies of S-oxiracetam.

Key words: S-oxiracetam, UPLC-MS/MS, Pharmacokinetics, Beagle dog, Plasma

CLC Number:

R965.2

WANG Wu-san, JI Hui, XIE Hai-tang, DAI Min, JIA Yuan-wei, LIANG Da-hu, YE Lei, RONG Zu-yuan. A sensitive and specific UPLC-MS/MS analysis and preliminary pharmacokinetic characterization of S-oxiracetam in Beagle dogs[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(9): 988-995.

References

[1] Hlinak Z, Krejc I.Oxiracetam pre- but not post-treatment prevented social recognition deficits produced with trimethyltin in rats[J].Behav Brain Res, 2005, 161(2):213-219.
[2] Hlinak Z, Vinsova J, Kasaffirek E.Effect of alaptide, its analogues and oxiracetam on memory for an elevated plus-maze in mice[J]. Eur J Pharmacol,1996, 314(1/2):1-7
[3] Mondadori C, Hengerer B, Ducret T, et al.Delayed emergence of effects of memory-enhancing drugs: implications for the dynamics of long-term memory[J].Proc Natl Acad Sci USA,1994, 91(6): 2041-2045.
[4] Mondadori C, Mobius HJ, Borkowski J.The GABAB receptor antagonist CGP 36742 and the nootropic oxiracetam facilitate the formation of long-term memory[J]. Behav Brain Res, 1996 ,77(1/2):223-225.
[5] Giovannini MG, Spignoli G, Magnani M, et al.Interaction between cognition enhancing agents and brain acetylcholine[J].Pharmacol Res Commun,1988,20: 181
[6] Bartolini L, Casamenti F, Pepeu G.Aniracetam restores object recognition impaired by age, scopolamine, and nucleus basalis lesions[J].Pharmacol Biochem Behave, 1996,53(2):277-283.
[7] Marchi M, Besana E, Raiteri M.Oxiracetam increases the release of endogenous glutamate from depolarized rat hippocampal slices[J]. Eur J Pharmacol, 1990,185(2/3):247-249.
[8] Lu Y, Wehner JM.Enhancement of contextual fear-conditioning by putative (+/-)-alpha-amino-3-hydrox y-5-methylisoxazole-4-propionic acid (AMPA) receptor modulators and N-methyl-D-aspartate( NMDA) receptor antagonists in DBA/2J mice[J].Brain Res, 1997, 768(1/2):197-207.
[9] Nicoletti F, Casabona G, Genazzani AA, et al.Excitatory amino acids and neuronal plasticity: modulation of AMPA receptors as a novel substrate for the action of nootropic drugs[J]. Funct Neurol,1992, 7(5):413-422.
[10] Govoni S, Lucchi L, Battaini F, et al.Protein kinase C increase in rat brain cortical membranes may be promoted by cognition enhancing drugs[J]. Life Sci,1992,50(16): 125-128.
[11] Fordyce DE, Clark VJ, Paylor R, et al.Enhancement of hippocampally-mediated learning and protein kinase C activity by oxiracetam in learning-impaired DBA/2 mice[J]. Brain Res, 1995,672(1/2):170-176.
[12] Nicolaus BJR.Chemistry and Pharmacology of Nootropics[J]. Drug Dev Res,1982,2:463-474
[13] Nardella C,Terracina L,Brunetti M,et al.Choline incorporation into phospholipids in brain areas from spontaneously hypertensive rats:effect of oxiracetam treatment[J].Farmaco,1991,46(9):1051-1059.
[14] Son J,Lee J,Lee M,et al.Rapid quantitative analysis of oxiracetam in human plasma by liquid chromatography/electrospray tandem mass spectrometry[J]. J Pharm Biomed Anal,2004,36(3):657-661.

[1]	WU Yujie, ZHAO Chengcheng, XI Qing. Evaluation of tegacycline regimens in treatment of gram-negative bacterial infections with Monte Carlo simulation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1027-1033.
[2]	LI Kun, LI Lulu, LI Nannan, HU Weihong, ZHOU Jianchao. Effects of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 767-774.
[3]	HE Xueru, LI Ying, MA Yinling, FU Yuhao, XUN Xuejiao, DONG Zhanjun. Pharmacokinetic interaction study between sorafenib and dapagliflozin in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 498-507.
[4]	HUANG Zhiwei, LI Yi, XU Xiaoyong, ZHANG Lei, SHEN Yifeng, LI Huafang. Comparison of calculation results of five population pharmacokinetic analysis tools [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 525-535.
[5]	LIU Tong, XU Jiaming, WANG Jinhuo, YIN Lei, CHEN Yongquan, GUO Jianrong. Changes of anesthetic drug concentration in plasma during isolation of autologous blood with acute isovolumic hemodilution and its influence on anesthetic effect after reinfusion [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 413-418.
[6]	LI Mengxue, HE Jie, YU Xiaxia, HU Linlin, SHAO Hua. Research progress in population pharmacokinetics of rituximab [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 468-474.
[7]	YAN Qiangyong, XIANG Daxiong, ZHU Ronghua, YANG Lingfeng, YANG Xiding, LI Jingjing, FAN Xiao, LIU Sai, XIONG Shoujun, FANG Pingfei. Bioequivalence study of cinacalcet hydrochloride tablets in healthy Chinese volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 171-177.
[8]	LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
[9]	ZHOU Jiating, ZHANG Xuan, XIE Zilan, LI Zhi. Interactions and clinical significance of gut microbiota and levothyroxine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1307-1314.
[10]	LI Xuejing, JIANG Jinping, LI Sining, WAN Linfei, ZHOU Xiangxiang, YANG Lian, LAN Ke. A bioequivalence study of generic and brand clozapine in schizophrenic patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1121-1130.
[11]	WU Lili, LIANG Zhi, HUANG Siyong, WANG Yan. Effect of augmented renal clearance (ARC) on the pharmacokinetics, efficacy, and safety of vancomycin in patients with infective endocarditis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1139-1145.
[12]	MA Shen, LIU Yushuo, TANG Hui, CHEN Wenbin, GAO Ling. Pharmacokinetics and clinical significance of drugs for improving nonalcoholic fatty liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 908-918.
[13]	DAI Jingyi, WANG Jingjing, ZHANG Jing, YU Jicheng, LI Nanyang, HUANG Zhiwei. Clinical application and research progress of inhaled methoxyflurane [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 808-813.
[14]	PAN Shu, WU Yijin, ZHANG Sasa, WANG Qihai, LUO Tingting, YIN Qin. Pharmacokinetics of methotrexate mediated by organic anion transporter 3 in adjuvant induced arthritis rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 516-525.
[15]	WU Juan, WANG Zhiqiang, ZHOU Renpeng, YANG Jingjing, QIN Huiling, ZHANG Qian, LU Chao, HU Wei. Bioequivalence trial of fasting oral sorafenib tosylate tablets in healthy Chinese subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 281-286.